OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Socioeconomic aspects of incretin-based therapy
Thomas Karagiannis, Eleni Bekiari, Απόστολος Τσάπας
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1859-1868
Open Access | Times Cited: 30
Thomas Karagiannis, Eleni Bekiari, Απόστολος Τσάπας
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1859-1868
Open Access | Times Cited: 30
Showing 1-25 of 30 citing articles:
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1206-1222
Open Access | Times Cited: 28
Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1206-1222
Open Access | Times Cited: 28
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 11
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 11
Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020
Benjamin G Mittman, Phuc Le, Julia Y. Payne, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 3, pp. 377-383
Closed Access | Times Cited: 6
Benjamin G Mittman, Phuc Le, Julia Y. Payne, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 3, pp. 377-383
Closed Access | Times Cited: 6
Investigating socioeconomic disparities in prescribing new diabetes medications in individuals with type 2 diabetes and very high cardiovascular risk in the Netherlands
Frank H. Ardesch, Rose J. Geurten, Jeroen N. Struijs, et al.
Primary care diabetes (2025)
Open Access
Frank H. Ardesch, Rose J. Geurten, Jeroen N. Struijs, et al.
Primary care diabetes (2025)
Open Access
Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management
Amruth Akhil Alluri, Yashaswi Guntupalli, Shruti Suresh Suvarna, et al.
Journal of Basic and Clinical Physiology and Pharmacology (2025)
Closed Access
Amruth Akhil Alluri, Yashaswi Guntupalli, Shruti Suresh Suvarna, et al.
Journal of Basic and Clinical Physiology and Pharmacology (2025)
Closed Access
Cardiovascular-kidney-metabolic syndrome: A step toward multidisciplinary and inclusive care
Sophie E. Claudel, Ashish Verma
Cell Metabolism (2023) Vol. 35, Iss. 12, pp. 2104-2106
Open Access | Times Cited: 11
Sophie E. Claudel, Ashish Verma
Cell Metabolism (2023) Vol. 35, Iss. 12, pp. 2104-2106
Open Access | Times Cited: 11
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review
Khalid M Hamed, Mohammed N Alosaimi, Bashaer A Ali, et al.
Cureus (2024)
Open Access | Times Cited: 4
Khalid M Hamed, Mohammed N Alosaimi, Bashaer A Ali, et al.
Cureus (2024)
Open Access | Times Cited: 4
GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Margaret A. Stefater‐Richards, Grace Jhe, Yanjia J. Zhang
PEDIATRICS (2025)
Closed Access
Margaret A. Stefater‐Richards, Grace Jhe, Yanjia J. Zhang
PEDIATRICS (2025)
Closed Access
Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐1RA ‐based weight‐loss therapies
Reimar W. Thomsen, Aurélie Mailhac, Julie B. Løhde, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Reimar W. Thomsen, Aurélie Mailhac, Julie B. Løhde, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease
André Scheen
Diabetes Epidemiology and Management (2024) Vol. 14, pp. 100197-100197
Open Access | Times Cited: 3
André Scheen
Diabetes Epidemiology and Management (2024) Vol. 14, pp. 100197-100197
Open Access | Times Cited: 3
The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes
Ioannis Avgerinos, Panagiota Kakotrichi, Thomas Karagiannis, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 5, pp. 511-522
Closed Access | Times Cited: 3
Ioannis Avgerinos, Panagiota Kakotrichi, Thomas Karagiannis, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 5, pp. 511-522
Closed Access | Times Cited: 3
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 3
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 3
Clinical efficacy and cost‐effectiveness of metformin in different patient populations: A narrative review of real‐world evidence
Anna Solini, Domenico Tricò
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S3, pp. 20-30
Open Access | Times Cited: 3
Anna Solini, Domenico Tricò
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S3, pp. 20-30
Open Access | Times Cited: 3
The role of incretin receptor agonists in the treatment of obesity
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4178-4196
Open Access | Times Cited: 3
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4178-4196
Open Access | Times Cited: 3
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
André Scheen
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1053-1062
Closed Access | Times Cited: 7
André Scheen
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1053-1062
Closed Access | Times Cited: 7
A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity
Ibrahim Abdullah Bin Ahmed
Journal of Obesity (2024) Vol. 2024, pp. 1-8
Open Access | Times Cited: 2
Ibrahim Abdullah Bin Ahmed
Journal of Obesity (2024) Vol. 2024, pp. 1-8
Open Access | Times Cited: 2
The Pathology of US Health Care—The Example of Weight Loss Medications
David Cutler
JAMA Health Forum (2024) Vol. 5, Iss. 8, pp. e243052-e243052
Open Access | Times Cited: 2
David Cutler
JAMA Health Forum (2024) Vol. 5, Iss. 8, pp. e243052-e243052
Open Access | Times Cited: 2
Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management
Kexin Lian, Kexin Zhang, Chengxia Kan, et al.
Life Sciences (2024) Vol. 351, pp. 122801-122801
Closed Access | Times Cited: 1
Kexin Lian, Kexin Zhang, Chengxia Kan, et al.
Life Sciences (2024) Vol. 351, pp. 122801-122801
Closed Access | Times Cited: 1
Health disparities in cirrhosis care and liver transplantation
David J. Goldberg, Julius Wilder, Norah A. Terrault
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 1
David J. Goldberg, Julius Wilder, Norah A. Terrault
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 1
Regional socioeconomic deprivation associated with the use of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in adults with type 2 diabetes in Germany
Marie Auzanneau, Jochen Seufert, Stefan Zimny, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 9, pp. 4116-4120
Open Access
Marie Auzanneau, Jochen Seufert, Stefan Zimny, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 9, pp. 4116-4120
Open Access
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes
Lidiya Kukova, Kashif M. Munir, Sayeed Ahmed, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 10, pp. 939-952
Closed Access
Lidiya Kukova, Kashif M. Munir, Sayeed Ahmed, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 10, pp. 939-952
Closed Access
Mechanisms by Which Pharmacotherapy May Impact Cancer Risk among Individuals with Overweight and Obesity
Edward R. Sauter, Tanya Agurs‐Collins
Cancers (2024) Vol. 16, Iss. 19, pp. 3275-3275
Open Access
Edward R. Sauter, Tanya Agurs‐Collins
Cancers (2024) Vol. 16, Iss. 19, pp. 3275-3275
Open Access
Uso de las terapias basadas en incretinas y estrategias educativas: un análisis desde los cuatro principios bioéticos
Leonardo Mancillas‐Adame, Sergio Zúñiga-Guajardo, Gabriela Morales-González, et al.
Revista Mexicana de Endocrinología Metabolismo y Nutrición (2024) Vol. 11, Iss. 93
Open Access
Leonardo Mancillas‐Adame, Sergio Zúñiga-Guajardo, Gabriela Morales-González, et al.
Revista Mexicana de Endocrinología Metabolismo y Nutrición (2024) Vol. 11, Iss. 93
Open Access
A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure
Ushna Gul, Thazin Nwe Aung, Mehwish Martin, et al.
Cureus (2024)
Open Access
Ushna Gul, Thazin Nwe Aung, Mehwish Martin, et al.
Cureus (2024)
Open Access
